IL-13 and eotaxin play important, inter-related roles in asthma models. In the lungs, CysLT, produced by the 5-LO-LTC4S pathway, mediate some local responses to IL-13 and eotaxin; in bone marrow, CysLT enhance IL-5-dependent eosinophil differentiation. We examined the effects of IL-13 and eotaxin on eosinophil differentiation. Semi-solid or liquid cultures were established from murine bone marrow with GM-CSF or IL-5, respectively, and the effects of IL-13, eotaxin, or CysLT on eosinophil colony formation and on eosinophil differentiation in liquid culture were evaluated, in the absence or presence of: a) the 5-LO inhibitor zileuton, the FLAP inhibitor MK886, or the CysLT1R antagonists, montelukast and MK571; b) mutations that inactivate 5-LO, LTC4S, or CysLT1R; and c) neutralizing mAb against eotaxin and its CCR3 receptor. Both cytokines enhanced GM-CSF-dependent eosinophil colony formation and IL-5-stimulated eosinophil differentiation. Although IL-13 did not induce eotaxin production, its effects were abolished by anti-eotaxin and anti-CCR3 antibodies, suggesting up-regulation by IL-13 of responses to endogenous eotaxin. Anti-CCR3 blocked eotaxin completely. The effects of both cytokines were prevented by zileuton, MK886, montelukast, and MK571, as well as by inactivation of the genes coding for 5-LO, LTC4S, and CysLT1R. In the absence of either cytokine, these treatments or mutations had no effect. 
Introduction
Allergic pulmonary inflammation and hemopoiesis are often regarded as unrelated processes. However, they share a number of chemical mediators endowed with systemic and local activities, which may provide means of communication between inflammatory sites and the bone marrow. Such communication might be important in the case of eosinophils, characteristically associated with chronic infiltrates in asthma, as eosinophils are produced in bone marrow and usually enter inflammatory sites as mature, postmitotic effector cells, which are programmed to undergo apoptosis in a relatively short time. As a consequence, long-term eosinophil infiltration is highly dependent on chronically increased eosinophilopoiesis [1, 2] . The search for chemical mediators capable of ensuring the long-distance, functional coupling between eosinophil infiltrates in the lungs, on the one hand, and eosinophil production in the bone marrow, on the other hand, is therefore of interest.
IL-5 is produced by Th2 lymphocytes in many sites, including the lungs and bone marrow [3] . IL-5 is indispensable to long-term eosinophilia, as it is the major factor inducing eosinophil differentiation from lineage-committed precursors [1] [2] [3] [4] [5] .
In addition, IL-5 extends the lifespan of infiltrating eosinophils and further activates or enhances their effector capabilities [6, 7] . However, IL-5 also promotes eosinophilia through mechanisms requiring its interaction with eotaxin and IL-13, two powerful chemical mediators of allergic inflammation. IL-5 interacts with eotaxin to initiate mobilization of bone marrow eosinophils to peripheral blood [8, 9] and with eotaxin and IL-13 to promote accumulation of eosinophils in the airways [10 -12] . In murine models of asthma, IL-5, eotaxin, and IL-13 are all considered essential for the maintenance of eosinophilic infiltrates [10, 11] . Promotion of eosinophilia is part of the wide-ranging role of IL-13 in asthma [13, 14] . Some studies have reported that IL-13 induces eotaxin production [15, 16] , thus raising the issue of whether its effects are mediated by eotaxin rather than synergic with those of eotaxin.
IL-13 has strong regulatory effects on various hemopoietic cell subtypes [17, 18] , and eotaxin acts on the bone marrow to mobilize eosinophil progenitors [8, 9] . Nevertheless, the effects of either cytokine on eosinophil production from bone marrow cells (eosinophilopoiesis) remain unexplored. We have addressed here the possibility that eotaxin and/or IL-13 modulate eosinophilopoiesis. In addition, we have evaluated the relationship of their modulatory effects to the production and action of CysLT, which are powerful mediators of allergic inflammation. Such a relationship is suggested by a number of previous studies as follows: a) some of the effects of IL-13 [19] and eotaxin [20] in inflammatory sites are blocked by interference with CysLT production and signaling; b) CysLT feed back positively on IL-13 production [21, 22] ; c) CysLT1Rs are required for production of eotaxin by IL-13-stimulated lung fibroblasts [23] ; d) CysLT stimulate eosinophil colony formation in humans [24] ; and e) CysLT strongly potentiate the effects of IL-5 in murine bone marrow culture [25] . As CysLT might provide an effective means to transduce the modulatory effects of eotaxin and IL-13 on eosinophilopoiesis, we examined here whether IL-13 or eotaxin requires CysLT production or signaling to modulate eosinophilopoiesis.
MATERIALS AND METHODS

Animals and animal procedures
Male and female BALB/c mice, bred at CECAL-FIOCRUZ (Rio de Janeiro, Brazil), were used at 6 -8 weeks of age. Animal housing and handling followed procedures approved by the Institutional Committee on Ethical Handling of Laboratory Animals (Protocol CEUA #P0107-02). Where indicated, mice lacking: a) the CysLT1R (Cys-LT1R KO), generated on the BALB/c and C57BL/6 background [26] ; b) the CysLT2R KO, generated on the C57BL/6 background [27] ; or c) LTC4S, generated in the BALB/c background [28] , bred at Brigham and Women's Hospital (Boston, MA, USA), were used, along with their wild-type littermate controls, as approved by the Animal Care and Use Committee of the Dana-Farber Cancer Institute (Brookline, MA, USA; Protocol Number 02-122). Where indicated, 5LO -/-mice, generated in the S129 background [29] and bred at the Department of Pharmacology, Faculdade de Medicina de Ribeirão Preto-Universidade de São Paulo (Ribeirão Preto, Brazil), were used as approved by the Institutional Ethics Committee.
Reagents
Heat-inactivated FCS and culture media were from Hyclone (Logan, UT, USA); agar Noble, L-glutamine, penicillin, streptomycin, and NBT/ BCIP from Sigma Chemical Co. (St. Louis, MO, USA); MK886 and MK571 from Calbiochem (Merck KgaA-affiliated, Darmstadt, Germany); LTD4 and montelukast from Cayman Chemical Co. (Ann Arbor, MI, USA); recombinant murine cytokines (GM-CSF, IL-5, IL-13, eotaxin) and antibodies specific for murine CCR3 or eotaxin, along with the appropriate control antibodies of the IgG2a isotype from R&D Systems (Minneapolis, MN, USA); SA-ALP from MabTech (Cincinnati, OH, USA); and liquid diaminobenzidin solution from Dako Cytomation (Dako Denmark A/S, Glostrup, Denmark).
Bone marrow cell studies
Bone marrow cells were obtained by flushing the two femurs of naive mice with RPMI-1640 medium containing 1% FCS. Initial studies were carried out in semi-solid cultures to define whether either cytokine had an impact on lineage-committed progenitors (colony-forming cells) [4, 30, 31] . Subsequently, to assess the effects of blockers (drugs and antibodies), liquid culture assays were used to facilitate sequential addition and proper mixing of these reagents to previously plated cells [32] . Blockers (inhibitors and antibodies) were added before positive stimuli (cytokines), all being present from the beginning of the culture without replenishment. Semi-solid (clonal) cultures were established by seeding 2 ϫ 10 5 cells in 1 mL in 35 mm triplicate culture dishes in a mixture of IMDM with 20% FCS and agar Noble (0.3% final concentration) in the presence of GM-CSF (2 ng/mL), alone or in association with IL-13 (0.01-1 ng/mL) or eotaxin (0.01-1 ng/mL). Colonies (defined as the progeny of a single progenitor, totaling Ͼ50 cells) were scored at Day 7. The frequency of eosinophil-containing colonies was determined on agar layers dried, mounted on microscope slides, stained for EPO [33] , and scored under high magnification (400ϫ) [4] . For representative images of EPOϩ and EPO-colonies, see Figure 1 . We have confirmed previously that these conditions were adequate for counting total myeloid colonies and for accurate differential counts of myeloid colony types on dried agar layers [4, 30, 31] . Liquid bone marrow cultures were established by seeding 10 6 bone marrow cells in 1 mL RPMI-1640 medium, with 10% FCS in the presence of IL-5 (1 ng/mL), alone or in association with IL-13 (0.01-1 ng/mL) or eotaxin (0.01-1 ng/mL) and incubated at 37°C, 5% CO 2 /95% air, for 7 days before counting total cells in a hemocytometer and determining the frequency of cells positive for EPO after staining of cytocentrifuge smears for EPO [33] . There is excellent agreement among eosinophil counts by EPO cytochemical staining, by CCR3 immunostaining, and by Giemsa hematological staining [32] . Eosinophil numbers were calculated from total and differential counts. These conditions were shown previously to support eosinophil proliferation and terminal differentiation and to allow detection of enhancing and suppressive effects [4, 30 -32] . In the absence of IL-5, eosinophil differentiation does not occur, and cultures present virtually no EPOϩ cells by Day 7 [4] , containing only macrophages and endothelial/stromal cells, which survive from the bone marrow inoculum, regardless of IL-5. Accordingly, no eosinophils were produced in the presence of eotaxin or IL-13 alone.
Eotaxin quantitation
Endogenous eotaxin production was quantitated (pg/mL) in 10ϫ concentrated culture supernatants (100 l) conditioned by 10 6 bone marrow cells for 4 days by ELISA (Quantikine TM ) using MAB420 and BAF420 anti-eotaxin antibodies, according to the manufacturer's instructions. ELISPOT assays were done in 96-well nitrocellulose plates (MAHA S4510, Millipore, Billerica, MA, USA), sensitized with 5 g/mL MAB420 (50 L/well, 16 h, 4°C), washed (3ϫ), and blocked (1 h, 37°C) in medium/10% FCS. Cultures were established for 5 days with bone marrow cells (200 L/well, 1-0ϫ10 5 cells) in the same medium plus cytokines (1 ng/mL IL-5 and IL-3, separately or in combination).
Plates were washed 3ϫ in PBS/1% FCS, incubated with biotinylated BAF420 antibody (1 g/mL, 4 h, 37°C), washed further 3ϫ in PBSTween 20, incubated with SA-ALP (1:1000, 50 L/well, 1 h, 37°C), and developed with NBT/BCIP (50 L/well, 40 min). ELISPOTs were photographed and enumerated in an Immunospot analyzer (CTL Analyzers, Cleveland, OH, USA).
Statistical analysis
Data (meanϮsem) were analyzed with Systat for Windows, Version 4, from Systat Inc. (Evanston, IL, USA), using factorial ANOVA with the Tukey (Honestly Significant Difference) correction for multiple comparisons of means observed with different treatments. For the entire study, the variation in baseline responses to [25, 30, 31, 33] . To facilitate comparisons between the effects of the two cytokines in the two different culture systems, the magnitude of the average increase in response to IL-5 or GM-CSF induced by IL-13, and eotaxin was expressed as percent enhancement relative to the respective (IL-5 or GM-CSF) controls, calculated as: [(response in the presence of IL-13 or eotaxin)-(response in the controls)/ (response in the controls)] ϫ 100.
RESULTS
Effects of IL-13 and eotaxin on eosinophilopoiesis
To determine whether IL-13 and eotaxin have an impact on eosinophilopoiesis, we initially evaluated their effects on formation of myeloid colonies by bone marrow progenitors cultured in the presence of the multilineage hemopoietic factor, GM-CSF. As shown in Figure 1A , eotaxin increased the total numbers of myeloid colonies significantly (which include eosinophil colonies) [4, 30 -32] , developing in the presence of GM-CSF from BALB/c bone marrow progenitors at 1 and 0.1 (but not 0.01) ng/ml (59.6Ϯ21.7% and 51.6Ϯ8.5% enhancement, Pϭ0.031 and Pϭ0.014, respectively). As shown in Figure 1B , in the presence of 1 ng/mL eotaxin (but not at lower concentrations), this increase in total colony numbers was accompanied by a significantly increased frequency of eosinophil colonies (142.7Ϯ41.1% increase, Pϭ0.028), which was mirrored by a nonselective decrease in the frequency of the other colony types (G, GM, and M). Eosinophil-containing colonies were "pure" (Eos) or "mixed" (GMEos), as described previously [4] , and types were increased similarly by eotaxin. As shown in Figure 1C , IL-13 significantly increased the total numbers of GM-CSFstimulated myeloid colonies at 1 ng/ml (62.8Ϯ10.7% enhancement, Pϭ0.008) but not at lower concentrations. As reported by others [23] , IL-13 by itself had no colony-stimulating activity (not shown). As further shown in Figure 1D , at this concentration, IL-13 increased the frequency of eosinophil colonies significantly (154.6Ϯ37.3% increase, Pϭ0.043)-pure and mixed-and G, GM, and M colony numbers were decreased to a comparable extent.
EPOϩ and EPO-colony numbers contributed to the increase in total colony counts observed with either cytokine. By far, EPOϩ colony counts made the largest contribution (two-thirds) to this increase in both cases, EPO-colony counts accounting for the remaining one-third.
We have further examined the possibility that these effects reflected, to some extent, the presence of a contaminant able to increase colony counts nonspecifically. By definition, this hypothetical contaminant would not lose its activity when treatments that specifically neutralize the cytokine are used. We took advantage of the availability of anti-CCR3 and antieotaxin neutralizing antibodies to block the effects of eotaxin on colony counts as a control for the presence of a nonspecific stimulus in the cytokine preparation. (i.e., a stimulus able to increase colony counts independently of eotaxin). Both neutralizing antibodies abolished the enhancing effect of eotaxin on total colony counts (Fig. 1E) as well as eosinophil-containing colonies (Fig. 1F) , thus ruling out the possibility of colonycount increases being induced by a contaminant rather than by an eotaxin itself. EPO- (Fig. 1G) and EPOϩ (Fig. 1H ) colonies, in these conditions, were identified unambiguously and conformed to morphological types described previously [4] .
We have further evaluated whether terminal differentiation of eosinophils from committed precursors in IL-5-stimulated liquid cultures would be affected by either cytokine. As shown in Figure 2A , the frequency of EPOϩ cells, comprising all stages of murine eosinophil differentiation, from the earliest precursors to fully mature eosinophils [4] , was increased significantly by eotaxin at 1 and 0.1 (but not 0.01) ng/mL. This increased frequency was reflected in a dose-dependent increase in eosinophil numbers recovered from the culture at Day 7, as shown in Figure 2B . Eotaxin did not induce eosinophil differentiation in the absence of IL-5 (not shown). As shown further in Figure 2C , the frequency of EPOϩ cells was also increased by IL-13 at 1 (but not 0.1-0.01) ng/ml. As shown in Figure 2D , this increased frequency was reflected in increased absolute numbers of EPOϩ cells. IL-13 by itself did not induce eosinophil differentiation (not shown).
Together, observations in semisolid and liquid culture conditions indicate that eotaxin and IL-13 enhance eosinophilopoiesis in the presence (but not in the absence) of GM-CSF and IL-5. As 1 ng/mL of either cytokine consistently had an enhancing effect, this was the concentration used in subsequent experiments designed to evaluate the contribution of CysLT in the observed cytokine effects (see below).
We controlled further for the accuracy of EPO staining in identifying eosinophils. Liquid cultures containing EPOϩ cells contained cells that expressed CCR3 and presenting the donut-shaped nuclei typical of mature murine eosinophils (Fig.  2E) ; EPO and CCR3 staining agreed with detection of eosinophils by Giemsa (Fig. 2F) . By contrast, neutrophils, identifiable by Giemsa staining, were not detectable by Day 7 in liquid cultures established with IL-5, alone or associated with eotaxin or IL-13 (Fig. 2F) . These different identification methods consistently support the idea that production of eosinophils, not of other bone marrow cell types, is enhanced by eotaxin and IL-13 in semisolid and liquid cultures.
Relationship between the effects of IL-13 and eotaxin
The similarity of effects for both cytokines, along with the published evidence that eotaxin is induced by IL-13 in some models, prompted us to examine whether the effectiveness of the latter would be affected by targeting production or function of the former. As shown in Figure 3A , IL-13 enhanced responses to IL-5 significantly (80.1Ϯ17.4% enhancement, Pϭ0.049) in the absence but not in the presence of specific neutralizing antibodies to eotaxin or to its receptor, CCR3. Unlike the specific neutralizing antibodies, an irrelevant antibody of the same isotype (IgG2a) at the same concentration had no effect. As shown further in Figure 3B , eotaxin enhanced responses to IL-5 significantly (91.1Ϯ21.1% enhancement, Pϭ0.004) in the absence but not in the presence of anti-CCR3. These observations confirm that eotaxin is acting, as expected, through CCR3 and further raise the possibility that the effects of IL-13 depend on the endogenous production of eotaxin in the culture.
We evaluated initially whether endogenous production of eotaxin was detectable in liquid bone marrow culture and whether an enhancing effect of IL-5, IL-13, or both on endogenous eotaxin production would be detectable. As shown in Figure 3C , small amounts of eotaxin were detected by ELISA in culture supernatants (0.1 ng/mL in 10ϫ concentrated supernatants, corresponding to 0.01 ng/mL in the culture), but no difference was observed between cultures maintained in medium alone and those stimulated by IL-5 or IL-13. In addition, numbers of ELISPOTs formed by bone marrow cells in the presence of IL-5 (19.3Ϯ4.8, meanϮsem) and IL-5 ϩ IL-13 (14Ϯ1.5) were not significantly different (Pϭ0.868).
In view of our inability to show induction of eotaxin production in response to IL-13, we examined the alternative possibility, namely that IL-13 does not induce eotaxin but still requires eotaxin to be present, as it acts synergically with endogenous eotaxin to stimulate eosinophilopoiesis. If so, enhancement of eosinophilopoiesis should be detectable in the presence of an association of IL-13 and eotaxin concentrations, which would have no effect if present separately. As shown in Figure 3D , IL-13, at concentrations that do not enhance eosinophilopoiesis significantly (0.1-0.01 ng/mL), strongly synergized with exogenous eotaxin at a very low concentration (0.01 ng/mL), which had no effect when added alone to the culture. These observations show that IL-13 and eotaxin, at low concentrations, enhance eosinophilopoiesis synergically. Furthermore, as the levels of eotaxin in the synergic combination approximate those produced spontaneously in the culture (see above), these results are consistent with a synergic, eotaxin-requiring mechanism for the effects of IL-13.
Role of CysLT in the modulation of eosinophilopoiesis by eotaxin and IL-13
As CysLT transduce the enhancing effects of nonsteroidal antiinflammatory drugs on eosinophilopoiesis [25] and mediate some effects of IL-13 and eotaxin in sites of allergic inflammation [19, 20] , we next evaluated whether targeting CysLT production or function would also have an impact on the ability of either cytokine to up-regulate eosinophilopoiesis. We took a comprehensive approach, targeting several critical steps in CysLT biosynthesis (involving 5-LO, FLAP, or LTC4S) and signal transduction (involving CysLT1R and CysLT2R). Where available, pharmacological and gene inactivation strategies were used to achieve comparable outcomes.
As shown in Figure 4A , eotaxin and IL-13 enhanced eosinophil production relative to IL-5 controls, in the absence but not in the presence of the 5-LO inhibitor, zileuton (98.6Ϯ8.5% and 98.0Ϯ17.9% enhancement, Pϭ0.001 and Pϭ0.013, respectively). By contrast, zileuton, in the absence of either cytokine, had no effect. As shown further in Figure 4B , the effects of both cytokines were blocked by the FLAP inhibitor MK886, which had no effect of its own, in the absence of either cytokine. Finally, as shown in Figure  4C , both were blocked completely by the CysLT1R antagonist, montelukast. Again, montelukast had no effect in the absence of eotaxin or IL-13. The response to IL-13 was also abolished by another CysLT1R antagonist, MK571 (not shown).
To confirm these pharmacological inhibition profiles, we examined the response to both cytokines in bone marrow cells from different strains of mice presenting distinct mutations related to the production (5-LO, LTC4S) or function (CysLT1R, CysLT2R) of CysLT.
As shown in Figure 5A , eotaxin and IL-13 enhanced (54.2Ϯ4.6% and 38.7Ϯ6.0%, PϽ0.001 and Pϭ0.002, respectively) IL-5-stimulated eosinophil production in cultured bone marrow from wild-type controls (S129) but not from 5LO -/-mice of the same genetic background. By contrast, as expected, the end-product, LTD4, was equally effective in wildtype and mutant bone marrow, showing that the defect in mutant bone marrow is a result of a lack of production rather than of responsiveness to CysLT. As shown further in Figure  5B , eotaxin and IL-13 were effective (114.9Ϯ39.7% and 126.0Ϯ39.8% enhancement, Pϭ0.033 and Pϭ0.033, respectively) on bone marrow from wild-type controls (BALB/c) but not from LTC4S-deficient mice of the same background.
Further evidence for the involvement of CysLT in mediating responses to both cytokines was provided by experiments with receptor-deficient mouse strains. As shown in Figure 6A , eotaxin and IL-13 enhanced eosinophil production in wildtype (BALB/c) bone marrow (73.3Ϯ32.0% and 82.2Ϯ32.1% enhancement, Pϭ0.022 and Pϭ0.022, respectively) but not CysLT1R-deficient bone marrow of the same background. As shown further in Figure 6B , eotaxin and IL-13 were effective (for the highest concentration of each, 170.0Ϯ43.1% and 164.4Ϯ54.5% enhancement, Pϭ0.018 and Pϭ0.002, respectively) in bone marrow from wild-type controls of a different background (C57BL/6) but were totally ineffective in the corresponding CysLT1R-deficient mice, thereby confirming that lack of effect is determined by inactivation of CysLT1R and apparently independent of other background genes.
By contrast, there was no impact of gene inactivation of CysLT2R on the ability of eotaxin to enhance IL-5-stimulated eosinophilopoiesis in bone marrow culture. CysLT2R-deficient mice and wild-type controls of the same background responded to eotaxin, and this response was abolished by montelukast, indicating the involvement of CysLT1R (not shown).
DISCUSSION
The findings reported here provide evidence of a novel role for eotaxin and IL-13. Both cytokines up-regulate eosinophilopoiesis in the presence of the more conventional hemopoietic cytokines, IL-5 and GM-CSF. In GM-CSF-stimulated semisolid cultures, both cytokines increased total colony counts, as expected from the multilineage activity of this hemopoietic factor. This increase was accounted for by a strong stimulation of eosinophil (EPOϩ) colony formation and by a weaker effect on other colony types. In IL-5-stimulated liquid cultures, both increased eosinophil differentiation exclusively, in a way consistent with the selectivity of this cytokine for eosinophils. The effects of eotaxin in semisolid and liquid culture were abolished by neutralizing antibodies to its receptor, CCR3. This indicates that these effects are a result of eotaxin itself, rather than of any contaminant. The evidence from semisolid and liquid cultures, taken together, indicates that eotaxin and IL-13 do not induce eosinophilopoiesis by themselves. Both modify, instead, the effects of GM-CSF and IL-5 in a way that increases eosinophil production. These observations expand the list of regulatory activities associated with IL-13 and eotaxin and document further an important effect of the latter during early stages of eosinophil development, as opposed to its well-recognized chemoattractant activity for terminally differentiated eosinophils.
This study documents further that the modulatory signals from both cytokines are strictly dependent on the generation of 5-LO products and on signaling through CysLT1Rs. Stimulation of eosinophilopoiesis by CysLT has been documented previously in humans [24] as well as in mice [25] . This mechanism was shown previously to be required for transducing the regulatory signals from nonsteroidal anti-inflammatory drugs in bone marrow culture [25] . We now show that it provides a mechanism for transducing the effects of cytokines on eosinophilopoiesis as well.
Together, our observations suggest that the primary cellular target of cytokine action in our system should be able to: a) express CCR3 constitutively and b) respond to eotaxin binding of CCR3 by producing CysLT. This profile likely corresponds to a cell of the eosinophil lineage in the early stage of a colony-forming cell (progenitor) or at later maturation stages (precursor). However, our observations suggest that noneosinophil (EPO-) colony counts may also increase to some extent as a result of eotaxin stimulation. As CCR3 is not necessarily expressed by progenitors of other hemopoietic lineages, it is possible that these primary targets release, following contact with eotaxin, secondary mediators capable of stimulating progenitors from other lineages in the presence of GM-CSF.
Although CysLT are important mediators of allergic inflammation [34] and have been shown to affect hemopoiesis in various ways [24, 25] , their possible contribution to the physiological regulation of hemopoiesis remains uncertain for a number of reasons. Local regulation of hemopoiesis by CysLT would require evidence of their production by bone marrow cells. To our knowledge, however, endogenous CysLT production from bone marrow cells in response to standard stimuli, such as Ca 2ϩ ionophore, has not yet been demonstrated. Alternatively, systemic regulation could, in principle, take place if CysLT were released in sufficiently large amounts in the circulation [34] . However, in these conditions, CysLT are known to have untoward cardiovascular, digestive, and respiratory effects, which would make this an unlikely mechanism for physiological regulation. Our observations, by providing a link between the effects of exogenously added eotaxin and local production of CysLT, may modify this picture substantially, as eotaxin is released from a number of sites and acts systemically in very low concentrations [35] , which are not associated with any untoward effects. Systemically administered eotaxin is active on bone marrow cells in vivo [9] . We have shown that: a) eotaxin, in effective concentrations in the culture, acts by inducing or facilitating activation of CysLT generation by bone marrow cells; and b) IL-13 greatly enhances the ability of eotaxin to do so. Hence, physiological regulation of eosinophilopoiesis by CysLT might be easier to understand if eotaxin, released from allergic inflammatory sites, acted systemically in bone marrow (especially if aided by IL-13) through local generation of CysLT.
Our observations show that the involvement of CysLT is separate from but dependent on induction of eosinophilopoiesis by IL-5. On the one hand, neither cytokine induced eosinophil production in the absence of IL-5. On the other hand, none of the inhibitors of CysLT synthesis and activity tested here and none of the gene inactivation strategies used had an effect on responses to IL-5 alone. Every one of them had a significant impact only in the presence of IL-13 or eotaxin. Overall, this supports our view that the 5-LO pathway does not contribute to signaling by IL-5 [25] , but endogenous CysLT production is important for the up-regulation of eosinophilopoiesis by eotaxin and IL-13.
The bone marrow may not be the only site where eosinophilopoiesis is susceptible to modulation by eotaxin and IL-13. An alternative possibility is that CysLT mediates regulatory effects of eotaxin and IL-13 on eosinophil progenitors and precursors recruited to the lungs. This possibility is supported by evidence that allergen-challenged lungs: a) are important sources of CysLT [17] [18] [19] [20] 27] ; b) produce IL-5, IL-13, and eotaxin [11] ; and c) accumulate eosinophil progenitors and precursors, including CD34ϩ IL-5R␣ϩ cells [36] , in response to systemically active signals originating in lung tissue [37] . Although it is of interest, this possibility was not examined here because of the necessary focus on bone marrow in this study.
One critical issue in this study concerns the mechanism underlying the dependence of IL-13 on eotaxin and CCR3. This has been examined with every tool available to us. Two distinct possibilities exist: a) an inductive mechanism, in which IL-13 depends on eotaxin (and on CCR3) to act, as it induces eotaxin, and that it is eotaxin acting as a secondary mediator, which enhances eosinophilopoiesis, by acting on CCR3; and b) a synergic mechanism, in exogenously added IL-13, acts synergically with endogenously produced eotaxin. These two possibilities can be distinguished by measuring the endogenous production of eotaxin by bone marrow cells and evaluating the effect, if any, of exogenous IL-13 on this production. Our results did not support an inductive mechanism: Although we detected eotaxin-producing cells in bone marrow culture and measured the eotaxin content of culture supernatants, neither was increased significantly following IL-13 exposure. Instead, our results showed that a synergic mechanism is possible, as we demonstrated effective enhancement of eosinophilopoiesis in cultures exposed to an association of IL-13 and eotaxin in concentrations that would have no effect if present separately in the culture. Our observations were also consistent with the possibility of a synergic interaction between IL-13 exogenously added at relatively high concentrations (1 ng/mL) and eotaxin at the concentration endogenously produced in the cultures (0.01 ng/mL).
A related and important issue is whether the CCR3 pathway would mediate CysLT production by bone marrow cells in sufficient amount. Our interpretation of the data is that it points unequivocally to CysLT being produced in the culture. Two different inhibitors of LT synthesis and a gene inactivation approach provided exactly the same result: When LT synthesis is inhibited, neither IL-13 nor eotaxin enhances eosinophil production. Furthermore, it is CysLT that are involved, as pharmacological and gene inactivation approaches are consistent in showing a role for LTC4S and for a specific subtype of the CysLTR. We consider our approach through a combination of pharmacological and genetic tools more rigorous than an attempt to quantify CysLT production over a 7-day period in culture, as it demonstrates unequivocally that CysLT production and CysLT signaling are necessary. Although an absolute requirement can always be demonstrated clearly, the measurement of the amounts produced is subject to numerous sources of uncertainty: a) CysLT production could be taking place anytime during the 7-day period of culture; b) CysLT are likely degraded during this period, and total production is not necessarily reflected in amounts measured at any given time-point; and c) CysLT production is associated with cells and likely to reach higher effective concentrations in the immediate vicinity of the producer cells than in the total volume of the culture, which is what is accessible for immunoassay. For these reasons, we take the view that synthesis of CysLT and signaling by CysLT1R are absolutely required for the effects we observed; the logical conclusion is that they are produced and act in this system.
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